GlaxoSmithKline reported that the company will eliminate approximately 1000 US sales jobs, or about 12 percent of its sales force in the country, by the end of the year as part of ongoing restructuring measures.


The company will eliminate about 1800 sales positions by not filling some posts that are already vacant and shifting some sales representatives to the vaccines sector. Staff dealing with primary care products will be most affected by the cutbacks, while GlaxoSmithKline said it would add positions in vaccines and specialty pharmaceuticals, including oncology, making the net number of job losses around 1000. The reductions will leave GlaxoSmithKline with about 7500 sales employees in the US, according to company spokesperson Mary Anne Rhyne.

In addition, sales staff will work within therapeutic areas rather than along geographic lines. The spokesperson explained that "realigning along therapeutic areas will enable us to respond to what we're hearing from health professionals. They want to see fewer reps but want to see people with specialised training and information."

GlaxoSmithKline will also consolidate its US headquarters in Research Triangle Park, North Carolina, Rhyne stated. The company had been operating out of two US headquarters, Research Triangle Park and a site in Philadelphia, where about 1500 employees are based. Rhyne indicated that there would be no immediate significant job cuts in Philadelphia. The moves are expected to produce "modest incremental savings," Rhyne noted.